IN THE SPECIFICATION:

Please amend Claim 24 without prejudice or disclaimer of the subject matter thereof. Please consider the claims as follows

Patients and their guardians signed written informed consent agreements, and the study was carried out in accordance with the Declaration of Helsinki as adopted and promulgated by the National Institutes of Health. All patients were medically healthy, without a current or past history of schizophrenia, psychotic disorders, substance abuse, other Axis I mental disorders, or seizure disorders. Patients were of average intelligence, with a mean IQ (+SD) of 90.33 (+ 9.90) (range = 74-110). Nine patients were medication free for greater than one year prior to the study; three ~~patents~~ patients were medication free for greater than six weeks prior to the study (one was previously on fluoxetine, one on sertraline and one on bupropion); and the remaining three patients were medication free for a minimum of two weeks prior to and throughout the study (one was previously on fluvoxamine and risperidone, one on sertraline and one on clonazepam).

Substitute the following paragraph for the last paragraph on page 27 of the PCT application:

All subjects were admitted into the General Clinical Research Center on the evening prior to each challenge. Following an overnight fast, the subject was awakened at 8:00 AM and an indwelling intravenous catheter inserted. At 8:30 AM vital signs were taken, and these continued to be monitored every half-hour. At 9:00 AM, 6 cc of blood were drawn and the oxytocin/placebo infusion was administered in a randomized double-blind fashion. The initial vial of Pitocin® (10u/mL) combined aseptically with a 1.0L bag of normal saline was first given at a rate of 10 ~~mu/hr~~ mL/hr which is equivalent to a dose rate of 0.1 units/hour. The infusion was initiated at a low rate to minimize potential side effects, and the rate gradually titrated up. Specifically, the dose rate was titrated every 15 minutes by 25 mL/hour in the first hour, 50 mL/hour in the second hour, 100 mL/hour in

the third hour, and held constant at the maximum rate of 700 mL/hr during the fourth hour. This created a range of dosing from 0.1 U/hour to 7 U/hour. See below:

| Time (hr) | Time (min) | infusion rate (ml/hr) | Dose rate (U/hr) |
|---|---|---|---|
| 0 | 0 | 10 | 0.1 |
| .25 | 15 | 25 | 0.25 |
| .5 | 30 | 50 | 0.5 |
| .75 | 45 | 75 | 0.75 |
| 1 | 60 | 100 | 1.0 |
| 1.25 | 75 | 150 | 1.5 |
| 1.5 | 90 | 200 | 2.0 |
| 1.75 | 105 | 250 | 2.5 |
| 2 | 120 | 300 | 3.0 |
| 2.25 | 135 | 400 | 4.0 |
| 2.5 | 150 | 500 | 5.0 |
| 2.75 | 165 | 600 | 6.0 |
| 3 | 180 | 700 | 7.0 |
| 3.25 | 195 | 700 | 7.0 |
| 3.5 | 210 | 700 | 7.0 |
| 3.75 | 225 | 700 | 7.0 |
| 4 | 240 | 700 | 7.0 |